Jun 15, 2024, 06:22
Ed Esplin: Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world
Ed Esplin, Clinical Geneticist at Invitae, shared a post on LinkedIn:
“1/3 of cancer patients with genetic testing in an Asian tertiary centre carried a germline PGV.
~75% of advanced cancer patients with actionable PGVs received corresponding targeted therapy.”
Read further in ESMO.
Read further in ASCO.
Source: Ed Esplin/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 28, 2024, 18:47
Dec 28, 2024, 18:43
Dec 28, 2024, 18:21
Dec 28, 2024, 18:21
Dec 28, 2024, 18:19
Dec 28, 2024, 18:19